Gyre Therapeutics (GYRE) Net Income (2010 - 2026)
Gyre Therapeutics (GYRE) reported Net Income of -$9.9 million for Q1 2026, down 364.01% year-over-year from $3.7 million in Q1 2025, and up 53.04% quarter-over-quarter from -$21.0 million in Q4 2025.
Gyre Therapeutics (GYRE) Net Income (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Net Income data on file, last reported at -$9.9 million in Q1 2026.
- Net Income for Q1 2026 came in at -$9.9 million, down 364.01% year-over-year; the trailing twelve-month figure through Mar 2026 was -$23.3 million (down 126.28% YoY), and the FY2025 annual result was -$9.7 million, down 136.98% from the prior year.
- Net Income climbed to -$9.9 million in Q1 2026 per GYRE's latest filing, from -$21.0 million in the prior quarter.
- Over five years, Net Income peaked at $51.6 million in Q2 2022 and troughed at -$101.0 million in Q4 2023.
- A 5-year average of -$6.2 million and a median of $2.9 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2026: Net Income surged 359.42% in 2022, then plunged 364.01% in 2026.
- A 5-year view of Net Income shows it stood at -$27.9 million in 2022, then slumped by 261.95% to -$101.0 million in 2023, then soared by 78.77% to -$21.4 million in 2024, then increased by 2.09% to -$21.0 million in 2025, then soared by 53.04% to -$9.9 million in 2026.
- Business Quant data shows GYRE's Net Income at -$9.9 million in Q1 2026, -$21.0 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | -9.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.86 Mn |
| Dec 31, 2025 | -20.99 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | -21.44 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 4.54 Mn |
| Mar 31, 2024 | 9.94 Mn |
| Dec 31, 2023 | -100.98 Mn |
| Sep 30, 2023 | 7.51 Mn |
| Jun 30, 2023 | 3.77 Mn |
| Mar 31, 2023 | 4.22 Mn |
| Dec 31, 2022 | -27.90 Mn |
| Sep 30, 2022 | -4.88 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | -14.54 Mn |
| Dec 31, 2021 | -20.31 Mn |
| Sep 30, 2021 | -25.22 Mn |
| Jun 30, 2021 | -19.90 Mn |